As viruses are intracellular parasites, they need a living cell to survive. July 21, - The story of Rational VaVaccines'ursuit of a therapeutic vaccine for genital herpes may go down as one of the strangest and most controversial chapters in the history of drug or vaccine development.
July 17, - This article sheds light on the molecular and structural interactions between HHV-6B tetramer and its host receptor, along with their neutralizing antibodies and their affinities, competition, and binding modes based on the HHV-6B tetramer structure are described. Our findings provide molecular and structural bases for a comprehensive understanding of these interactions and relationships.
July 16, - Herpes simplex virus type 1 in Europe: a systematic review, meta-analyses, and meta-regressions. The results showed that more than two-thirds Around The results also showed that half of the first-episode genital herpes cases in Europe were already due to HSV-1 instead of HSV-2 infection. July 9, - Meta-analytic approach for transcriptome profiling of herpes simplex virus type 1.
June 13, - Study: 'I' this review, I have briefly described some of the models available and then more thoroughly describe the guinea pig model of acute and recurrent genital herpes infections.
As discussed, the guinea pig model most closely mimics human disease and provides several essential endpoints for evaluating vaccines and antivirals.
May 22, - Study: In pigs, assess the properties and efficacy of an R2 vaccine derived from the alpha-herpesvirus, pseudorabies virus PRV. We demonstrate that the PRV R2 vaccine does not invade the porcine peripheral nervous system within detection limits. Furthermore, after a single intranasal vaccination, R2 conferred protection to pigs subsequently challenged with a virulent PRV field strain NIA These findings support that the R2 vaccine design is non-neuroinvasive and is an effective vaccine in the context of a natural host.
May 19, - Genocea Biosciences, Inc. May 6, - Newly published research is the first to show in a lab model that the herpes simplex virus HSV-1 might cause AlAlzheimer'sIn the study; scientists found that mini 3D models of the human brain, when infected with the virus that causes cold sores, developed hallmarks of AlAlzheimer'sincluding amyloid plaque-like formations and neuroinflammation.
May 1, - The WHO issued a statement saying, 'About half a billion people worldwide live with genital herpes. New estimates show that several billion have an oral herpes infection, highlighting the need to improve awareness and scale-up services to prevent and treat herpes.
March 2, - WSU researchers recently published a study in the American Society for MiMicrobiology'sournal mSphere that is the first to identify how one of the virus proteins acts as a critical signaler for the virus to succeed in infecting a cell. April 27, - Study: Based on our revised annotation of viral transcripts and ORFs, we extended the existing nomenclature to include all our novel viral gene products.
This did not involve any renaming of previously described viral gene products. This will facilitate functional studies on the viral gene products and their transcriptional and translational regulation. January 10, - Sanofi announced Phase 1 and 2 studies were posted.
The study's primary objectives are: To describe the safety profile of different investigational vaccine regimens against herpes simplex virus type 2 HSV In addition, to evaluate the efficacy of the investigational vaccine regimens concerning the frequency of herpes simplex virus HSV deoxyribonucleic acid DNA detection in the genital area shedding rate following a 2 dose vaccine schedule; the proportion of participants free of HSV genital recurrence at 6 months after the 2-dose vaccine schedule.
January 8, - Candel Therapeutics announced that the acquisition consolidates a next-generation herpes drug development platform and manufacturing expertise tailored to multiple tumor types and indications. This study confirms the previously demonstrated safety of COR-1 in humans and indicates a potential for using COR-1 as a therapy to reduce viral shedding in HSV-2 infected subjects. It serves as a general blueprint for investigating heterogeneous cell states in virus infection.
November 21, - Cornell University researchers hoping to learn what switches this life-long virus between latent and lytic stages may have found the 'hidden 'answer to this question. November 18, - Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. The contribution is likely to be most significant in areas where HSV-2 is highly prevalent, particularly in Africa.
New preventive interventions against HSV-2 infection could not only improve the quality of life of millions of people by reducing the prevalence of herpetic genital ulcer disease but could also have an additional, indirect effect on HIV transmission.
September 20, - A new herpes simplex 2 virus vaccine study in animals reported an experimental vaccine developed at the University of Pennsylvania had prevented genital lesions in 98 percent of mice and guinea pigs tested. Friedman and colleagues just published a paper in Science Immunology in which they describe the trivalent herpes vaccine that they developed and its efficacy in animal models. This trivalent vaccine protected mice and guinea pigs from developing genital lesions and reduced viral shedding.
July 23, - X-Vax Technology, Inc. June 15, — A new study published in Nature on June 12, , by Yale researchers offered insights that could lead to a better genital herpes therapeutic vaccine.
Latent herpes viruses lurk in clusters of nerve cells called ganglia, and researchers have found that some ganglia are harder to reach than others. Over the years, they discovered that some AAV strains are better suited than others to find specific types of nerve clusters, and this has helped them fine-tune the selection of these delivery viruses to match infected cells in different places. By selecting vectors that are primed for harder-to-reach nerve clusters, the group expects to continue improving their ability to eradicate the virus.
As the Jerome Lab prepares to see if its gene therapy can block genital herpes, they are also reshuffling their selection of vector viruses and meganucleases to target nerve cells infected by HSV They are collaborating with Dr.
Barry Stoddard , a Hutch colleague who specializes in discovering the structure of proteins, to custom-design a set of meganucleases that they hope will work even better than the first.
Somewhat surprisingly, they found that this newfangled precision cutting tool did not perform as well as their meganucleases. One possible reason: CRISPR is a much larger molecule, and the comparatively smaller meganucleases are easier to package and deliver to nerve cells. It takes about three months to make a meganuclease," Stoddard said. Experience has shown, however, that the Jerome Lab is endowed with patience.
Their year trek has proven the potential of gene therapy for erasing herpes, yet the road ahead will undoubtedly require deep reserves of patience and persistence. Meganucleases used in the experiments described in the Nature Communications paper were supplied by Paris-based Cellectis SA.
Note: Scientists at Fred Hutch played a role in developing these discoveries, and Fred Hutch and certain of its scientists may benefit financially from this work in the future. Reach him at srussell fredhutch. Are you interested in reprinting or republishing this story? Be our guest! Therapeutic vaccines aim to prevent HSV recurrences or minimise disease severity and duration, thereby reducing transmission.
Research indicates that to be effective, therapeutic vaccines need to stimulate strong cell-mediated immune responses. Vaccines have induced HSV-specific antibody responses alone but have failed to protect recipients from recurrences. Immunocompromised patients can develop life-threatening infections due to HSV such as encephalitis or pneumonitis , and in these cases, acyclovir is often used in high doses.
If acyclovir-resistant HSV is encountered, it is usually treated with cidofovir and foscarnet; however, these drugs can cause kidney toxicity. Prophylactic treatment can also be administered with antiviral drugs to prevent or shorten future outbreaks.
Clinical trials are carried out before a new drug or treatment is released to the public to test its efficacy and safety. They are led by a team comprised of researchers, doctors, nurses, and other healthcare personnel. Participation in these trials is entirely voluntary, and patients can leave the trial at any point if they wish to do so. Joining a clinical trial allows patients to gain more control over their treatment, and to be treated by experts in the field.
Herpes clinical trials are carried out to test new treatments that could possibly cure the disease, and to create and test vaccines to prevent infection. If you have been infected with the herpes simplex virus, make sure to adopt habits that minimize the risk of infecting other people, such as using condoms to prevent infection during intercourse, avoiding having multiple sex partners, avoiding intercourse during an active outbreak.
Make sure to discuss all your therapeutic options with your doctor, since the proper treatment can make outbreaks shorter and less painful. Seek professional help if you are having difficulty coping with the diagnosis.
It is normal to feel shock, anger and embarrassment after diagnosis; however, it is important to know that although there is a stigma associated with herpes, it is a manageable condition that hardly ever leads to serious complications and you can lead a normal life after being infected.
What is Herpes?
0コメント